Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary ...
NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...
Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate. | Electra ...
INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.
When teenagers or adults do get hand, foot and mouth disease, symptoms are usually mild or may not appear at all. Some adults ...
A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a noninvasive assessment tool may help identify those at increased risk, ...
The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...
A combined analysis of blood tests to measure three biomarkers linked to higher risk of cardiovascular disease—lipoprotein a ...
Share on Pinterest A new study found that young adults in good cardiovascular health tended to maintain it as they got older. Studio Firma/Stocksy United New research shows that building heart-healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback